Preventive Approach Using Venlafaxine

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mit Ghamr Oncology Center
• Treatments: Gabapentin; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• Patients >24 years of age, men or women to lower risk of suicidal tendency.

• Patients with histologically proven cancer

• Patients receiving oxaliplatin or taxanes-based regimen

• WHO performance status of 0-2

• serum AST or ALT no higher than two times the upper limit of normal

• serum creatinine level less than 2 mg/dL

• platelet count of at least 100,000/mm3

• absolute neutrophil count of at least to 1.0 G/L

• Female patients, those with a negative urine pregnancy test.

Exclusion Criteria:

• Patients with brain or leptomeningeal metastasis.

• Patients with previous platinum-based chemotherapy

• Patients with history of alcoholic intoxication, diabetes, preexisting neuropathy or unstable psychological conditions.

• Patients with history of calcium/magnesium concomitant infusions, use of antiepileptics, antidepressants or lithium.